ZYME · Zymeworks Inc. · Webcasts, Transcripts & Audio
$26.00
-0.04 (-0.15%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q1 2026 earnings call transcript
Market Cap
$1.80B
Shares
69.03M
Volume · Nov 18
1.09M
Avg daily vol (3M)
1.08M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Zymeworks Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Zymeworks Inc. (ZYME), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Zymeworks Inc. (ZYME) November 17, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-12
Zymeworks Inc. (ZYME) November 12, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-11
Zymeworks Inc. (ZYME) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-10
Zymeworks Inc. (ZYME) November 10, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-09
Zymeworks Inc. (ZYME) Q3 2026 Earnings Call
Revenue
$256.46M
▲ 828.7% YoY Diluted EPS
$2.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-28
Zymeworks Inc. (ZYME) September 28, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-09-28
Zymeworks Inc. (ZYME) Q2 2026 Earnings Call
Revenue
$4.59M
▼ 90.6% YoY Diluted EPS
$-0.62
▼ 2166.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Zymeworks Inc. (ZYME) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-08
Zymeworks Inc. (ZYME) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Zymeworks Inc. (ZYME) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Confident tone
ADC pipeline and AACR data
Zanidatamab regulatory milestones
Royalty aggregation business model
Revenue
$2.41M
▼ 91.1% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-21
Zymeworks Inc. (ZYME) April 21, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-02
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Confident tone
Royalty Pharma royalty-backed note financing
Royalty and milestone economics from collaborations
Zanidatumab GEA regulatory and commercial progress
Revenue
$2.52M*
▼ 91.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
Confident tone
ZW191 Phase I ADC (folate receptor alpha)
ZW251 Phase I ADC (GPC3, hepatocellular carcinoma)
DLL3 T-cell engager (preclinical/ZW171)
Revenue
$27.61M
▲ 72.6% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript
Confident tone
Wholly-owned ADC pipeline (ZW171, ZW191, ZW251, ZW220)
Preclinical IL-4/IL-33 bispecific (ZW1528) for COPD
Timing and disclosure of ZW191 data
Revenue
$48.73M
▲ 153.2% YoY Diluted EPS
$0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript
Positive tone
Bispecific T-cell engager vs ADC strategy
Pipeline and preclinical data
Partnerships and milestones
Revenue
$27.11M
▲ 170.3% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-08
Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript
Positive tone
Partnership milestones and revenue
ADC programs (ZW251, ZW220, ZW191)
Financial performance and operating expenses
Revenue
$31.03M*
▲ 83.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
Positive tone
Partner programs and licensing revenue
Wholly owned pipeline progress (ZW171, ZW191, ZW220, ZW251)
Zanidatamab (Zani) updates with Jazz Pharmaceuticals
Revenue
$16.00M
▼ 3.1% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript
Positive tone
Wholly-owned pipeline advancement
Zanidatamab regulatory progress
Mesothelin T-cell engager safety and design (ZW171)
Revenue
$19.24M
▲ 174.8% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript
Confident tone
Zanidatamab Partnership Progress
TriTCE Trispecific Platform
Preclinical Pipeline / ADC and Multispecifics
Revenue
$10.03M
▼ 71.8% YoY Diluted EPS
$-0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript
Confident tone
Zanidatamab commercial outlook
Partner execution (Jazz/BeiGene)
5x5 early-stage pipeline
Revenue
$16.93M*
▼ 95.8% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Zymeworks Inc. (ZYME) Q3 2023 Earnings Call Transcript
Revenue
$16.51M
▲ 527.4% YoY Diluted EPS
$-0.41
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Zymeworks Inc. (ZYME) Q2 2023 Earnings Call Transcript
Revenue
$7.00M
▲ 28.7% YoY Diluted EPS
$-0.76
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Zymeworks Inc. (ZYME) Q1 2023 Earnings Call Transcript
Revenue
$35.58M
▲ 1756.9% YoY Diluted EPS
$-0.37
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Zymeworks Inc. (ZYME) Q4 2022 Earnings Call Transcript
Revenue
$402.49M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Zymeworks Inc. (ZYME) Q3 2022 Earnings Call Transcript
Revenue
$2.63M
▼ 40.1% YoY Diluted EPS
$-0.72
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Zymeworks Inc. (ZYME) Q2 2022 Earnings Call Transcript
Revenue
$5.44M
Diluted EPS
$-0.97
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
Zymeworks Inc. (ZYME) Q1 2022 Earnings Call Transcript
Revenue
$1.92M
Diluted EPS
$-1.19
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
Zymeworks Inc. (ZYME) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
1937653
CUSIP
98985Y108
13F (30d)
206 filings
192 filers
Visit website
Investor relations